The Redmond (Wash.) Police Department is deploying a new tool in its fight against illicit drugs. The agency announced Tuesday that it’s using a handheld narcotics analyzer called TruNarc that… Read More
CaaMTech, a Seattle-area startup developing new psychedelic agents, has raised $22 million in funding, the company announced this week. The company is synthesizing an array of new compounds similar to… Read More
Connie Wan is no different than any other parent who has struggled to get a little kid to take medication during a bout of sickness. She fumbled with syringes and… Read More
Shares of cancer drug maker Seattle Genetics soared more than 17 percent Monday morning following positive results for a new drug that fights aggressive breast cancers. Tucatinib is a daily… Read More
Seattle startup SEngine Precision Medicine has raised $5.1 million in fresh funding as it looks to commercialize a platform that can match cancer patients to the right drug and aid… Read More
Physicians and regulators keep close tabs on how different drugs interact. But what about interactions involving dietary supplements? “There’s just no way for anybody to keep up with the combinations… Read More
Modern drugs are lifesavers. But they can — and frequently do — cause more harm than good. Here’s a staggering fact: around 128,000 people die each year from a bad… Read More
Cancer drugmaker Seattle Genetics reported stronger-than-expected revenues for the second quarter as its stock rose more than 8 percent in after-hours trading. The Bothell, Wash.-based drugmaker posted $218 million in… Read More
Sound Pharmaceuticals, a Seattle-based drugmaker that is creating a first-of-its-kind treatment for hearing loss, recently reported encouraging top-line results from a Phase II clinical trial and is eyeing a potential… Read More
Biotech giant Amgen is putting up the money to fund three research projects in partnership with the University of Washington’s Institute for Protein Design (IPD). Amgen declined to disclose the… Read More
Alder BioPharmaceuticals has raised $170 million in a stock offering and is ramping up operations after filing an FDA application for eptinezumab, a therapy for patients with chronic migraines. Alder… Read More
Seattle Genetics on Thursday reported higher-than-expected losses for the fourth quarter, sending shares down 8 percent in after-hours trading. Quarterly revenues came in at $175 million, above Wall Street expectations… Read More
CTI BioPharma announced Thursday that it will let go of half its employees in order to create more runway to develop its experimental drug Pacritinib, which treats the blood cancer… Read More
Seattle-based biotech firm Impel NeuroPharma closed its latest round of funding, bringing in $67.5 million to develop treatments for central nervous system disorders, such as migraines and Parkinson’s. This is… Read More
Pillsy has launched a subscription service that works alongside the Seattle-based startup’s smart pill bottles, reminding users to take their supplements and automatically ordering refills on their behalf when it detects… Read More
Listening to music can be a very personal journey for some people, serving as a guiding light or emotional girder, depending on the situation. For subjects undergoing psychedelic treatment at… Read More
Even if you’re at work and not currently high, there’s a good chance you’re going to have a laugh while watching this new commercial from Briteside, an Oregon-based marijuana delivery… Read More
Revalesio, a biomedical company headquartered in Tacoma, Wash., says it’s been cleared to benefit from federal incentives for the development of a drug that could help treat a neurodegenerative disease… Read More
After flirting with the idea for years, Amazon may finally be ready to really go after the pharmaceutical market. Anonymous sources reportedly told CNBC tech reporter Christine Farr that Amazon… Read More
Dendreon, the once-promising Seattle biotechnology company that developed treatments for prostate cancer, will be sold to Quebec-based Valeant Pharmaceuticals International Inc. after no additional qualified bids emerged in the company’s bankruptcy… Read More